GLP1R and pancreatic neoplasm: However, recently published randomized controlled cardiovascular outcome trials with longer follow-up duration and better design did not show any significantly increased risk of either pancreatitis or pancreatic cancer in patients with type 2 diabetes who received GLP-1-based therapies [10,11].